Lyell Immunopharma (LYEL) to Release Earnings on Wednesday

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) is expected to post its quarterly earnings results on Wednesday, February 26th. Analysts expect Lyell Immunopharma to post earnings of ($0.20) per share for the quarter.

Lyell Immunopharma Price Performance

Shares of LYEL stock traded up $0.04 on Friday, hitting $0.70. The stock had a trading volume of 1,094,328 shares, compared to its average volume of 1,277,053. The firm has a market capitalization of $204.72 million, a P/E ratio of -0.89 and a beta of -0.35. Lyell Immunopharma has a 1 year low of $0.51 and a 1 year high of $3.26. The company's 50 day moving average price is $0.61 and its 200-day moving average price is $1.00.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Bank of America downgraded Lyell Immunopharma from a "buy" rating to an "underperform" rating and cut their price objective for the company from $6.00 to $1.00 in a report on Wednesday, October 30th. HC Wainwright reiterated a "neutral" rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, November 12th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.